1
|
Woopen H, Sehouli J, Davis A, Lee Y, Cohen P, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta M, Sundar S, Suzuki N, van Dorst E, Joly F. Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396]. Cancer Treat Rev 2022; 109:102431. [DOI: 10.1016/j.ctrv.2022.102431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Armbrust R, Richter R, Woopen H, Hilpert F, Harter P, Sehouli J. Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. ESMO Open 2021; 6:100081. [PMID: 33743329 PMCID: PMC8010392 DOI: 10.1016/j.esmoop.2021.100081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 01/11/2021] [Accepted: 01/30/2021] [Indexed: 11/18/2022] Open
Abstract
Objective Recurrent ovarian cancer is an incurable disease with variable but poor prognosis. Health-related quality of life (HRQoL) is a patient-reported outcome measure generally applied to measure effects of therapies. Our aim was the development and validation of a risk score for the prediction of short-term mortality using the combination of sociodemographic and clinical factors and HRQoL. Methods For exploratory and validation analysis, the North-Eastern German Society of Gynecological Oncology (NOGGO) and Working Group Gynecological Oncology (AGO) study databases were screened for trials. Only trials which obtained defined HRQoL measurements were included in the final analysis. Multivariable logistic regression analyses were used to identify risk factors and their weighting for the risk score. Modulation with cubic regression analyses revealed median survival and short-term mortality defined as 1-year mortality for each value. Results For exploration, 974 patients from three clinical studies of the NOGGO and for validation, 1235 patients from several clinical studies of the AGO were eligible. The risk score included platinum-free interval, performance status, age, global QoL and nausea/vomiting. Receiver operating characteristic analysis showed a good predictive value with an area under the curve of 0.81 for model 1 in the exploration and 0.74 in the validation. Short-term mortality in model 1 was 8.2%, 23.5% and 58.4% in the exploration sample, and 19.7%, 38.1% and 63.4% in the validation sample for patients under low, medium and high risk, respectively. Conclusions This risk score discriminates well between recurrent ovarian cancer patients under low, medium and high risk of short-term mortality. It may help to identify a risk group under high risk for short-term mortality that can be used for randomization in clinical trials and may support decision making for palliative chemotherapy. This newly developed NOGGO-AGO QoL prognosis score clearly discriminates recurrent ovarian cancer (rOC) patients under low, medium and high risk for short-term survival (<1 year). The risk score included platinum-free interval, performance status, age, global QoL and nausea/vomiting. NOGGO-AGO QoL score can be used for stratification or randomization in clinical trials and for identification of a group under high risk for short-term mortality. It may also help the decision making for chemotherapy and provide more precise information of further life expectation for rOC patients.
Collapse
Affiliation(s)
- R Armbrust
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - R Richter
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - H Woopen
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - F Hilpert
- Department of Gynecology, Krankenhaus Jerusalem Hamburg, Hamburg, Germany
| | - P Harter
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - J Sehouli
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
| |
Collapse
|
3
|
Woopen H, Richter R, Inci G, Alavi S, Chekerov R, Sehouli J. The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients. Support Care Cancer 2019; 28:1997-2003. [PMID: 31385100 DOI: 10.1007/s00520-019-05000-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2019] [Accepted: 07/16/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND Aim of this study was to analyze the impact of pain on quality of life and survival in recurrent OC patients. METHODS Raw data including the QLQ-C30 questionnaire from three phase II/III trials ("Topotecan phase III," "Hector," and "TRIAS") conducted by the North-Eastern German Society of Gynecological Oncology (NOGGO) were synthesized and analyzed using logistic and Cox regression analyses. RESULTS Data on pain was available for 952 patients out of 1226. Moderate to severe pain, which was defined as pain ≥ 50 in the QLQ-C30 symptom scale, was experienced by more than one-third of patients (36.6%). A total of 31% were taking non-opioid pain medication and 16% opioids. Median age at randomization was 61 years (range 25-84). Most patients (84.7%) were diagnosed in FIGO III/IV. Pain was independent from age, FIGO stage, grading, amount of recurrences, and chemotherapy-free interval. ECOG was significantly worse in patients with pain (p < 0.001). Fatigue, nausea/vomiting, sleeping disorders, and abdominal symptoms such as loss of appetite, diarrhea, and constipation were more frequently found in patients with pain (all p < 0.001). Quality of life was significantly diminished (p < 0.001). Pain was also an independent marker for overall survival (OS). Median OS was 18.2 months in patients with pain compared with 22.0 months in patients without pain (p = 0.013, HR 1.25, 95% confidence interval 1.05-1.48). OS was shorter in patients with pain and without pain medication compared with those on sufficient pain medication, whereas OS was mostly decreased in patients having pain despite pain medication (18.5, 19.6, and 15.0 months respectively; p = 0.026). Progression-free survival and prior treatment discontinuation were not associated with pain. CONCLUSION Best supportive care including sufficient pain medication should be delivered as early as possible because effective pain management is crucial for both quality of life and overall survival in patients with recurrent ovarian cancer.
Collapse
Affiliation(s)
- H Woopen
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
| | - R Richter
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - G Inci
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - S Alavi
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - R Chekerov
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - J Sehouli
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology with Center for Oncological Surgery, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| |
Collapse
|
4
|
Rolf C, Woopen H, Richter R, Pirmorady Sehouli A, Braicu EI, Schnuppe K, Sehouli J. Langzeitüberlebende mit Eierstockkrebs und Sexualität. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1678373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- C Rolf
- Gynäkologie, Charité Universitätsmedizin Berlin
| | - H Woopen
- Gynäkologie, Charité Universitätsmedizin Berlin
| | - R Richter
- Gynäkologie, Charité Universitätsmedizin Berlin
| | | | - EI Braicu
- Europäisches Kompetenzzentrum für Eierstockkrebs (EKZE), Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin
| | - K Schnuppe
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Klinik für Frauenheilkunde, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin
| | - J Sehouli
- Gynäkologie, Charité Universitätsmedizin Berlin
| |
Collapse
|
5
|
Woopen H, Braicu I, Richter R, Schnuppe K, Krabisch P, Boxler T, Emons G, Glajzer J, Rose M, Erdur L, Lindhorst R, Endres M, Hühnchen P, Vergote I, Berger R, Marth C, Sehouli J. Quality of life and symptoms in longterm survivors with ovarian cancer: It’s still an issue. Expression VI – Carolin meets HANNA – holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.148] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Woopen H, Richter R, Braicu EI, Keller M, Glajzer J, Rose M, Erdur L, Krabisch P, Emons G, Lindhorst R, Endres M, Hühnchen P, Marth C, Berger R, Vergote I, Sehouli J. Characteristics of long-term survivors with ovarian cancer: Expression VI-Carolin meets HANNA – the international NOGGO, ENGOT and GCIG survey. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- H Woopen
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Deutschland
| | - R Richter
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Deutschland
| | - EI Braicu
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Deutschland
| | - M Keller
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Berlin, Deutschland
| | - J Glajzer
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Deutschland
| | - M Rose
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Psychosomatik, Berlin, Deutschland
| | - L Erdur
- Charité – Universitätsmedizin Berlin, Campus Mitte, Klinik für Psychosomatik, Berlin, Deutschland
| | - P Krabisch
- Klinikum Chemnitz, Gynäkologie, Chemnitz, Deutschland
| | - G Emons
- Universität Göttingen, Gynäkologie, Göttingen, Deutschland
| | - R Lindhorst
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Kardiologie, Berlin, Deutschland
| | - M Endres
- Charité – Universitätsmedizin Berlin, Klinik für Neurologie, Berlin, Deutschland
| | - P Hühnchen
- Charité – Universitätsmedizin Berlin, Klinik für Neurologie, Berlin, Deutschland
| | - C Marth
- Universitätsklinik Innsbruck, Gynäkologie, Innsbruck, Österreich
| | - R Berger
- Universitätsklinik Innsbruck, Gynäkologie, Innsbruck, Österreich
| | - I Vergote
- University of Leuven, Leuven, Belgien
| | - J Sehouli
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie, Berlin, Deutschland
| |
Collapse
|
7
|
Braicu E, Sehouli J, Richter R, Vergote I, Concin N, van Nieuwenhuysen E, Achimas P, Berger A, Fetica B, Mahner S, Glajzer J, Papadia A, Woelber L, Gasparri M, Vanderstichele A, Benedetti Panici P, Mueller M, Ruscito I, Zimmer J, Woopen H. Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Woopen H, Wimberger P, Mustea A, Oskay-Oezcelik G, Keller M, Richter R, Harde J, Klawitter S, Wegenaer A, Tomé O, Sehouli J. Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Buttmann-Schweiger N, Barnes B, Woopen H, Braicu I, Pietzner K, Sehouli J. Retrospective study of long-term epithelial ovarian cancer survivors: clinical data and population-based cancer registry data. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1606027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - B Barnes
- Robert Koch-Institut, Zentrum für Krebsregisterdatem (ZfKD), Berlin
| | - H Woopen
- Universitätsmedizin Berlin Charité, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin
| | - I Braicu
- Universitätsmedizin Berlin Charité, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin
| | - K Pietzner
- Universitätsmedizin Berlin Charité, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin
| | - J Sehouli
- Universitätsmedizin Berlin Charité, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin
| |
Collapse
|
10
|
Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker L, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau A, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Ann Oncol 2016; 27:2236-2241. [DOI: 10.1093/annonc/mdw418] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 07/20/2016] [Accepted: 08/23/2016] [Indexed: 11/13/2022] Open
|
11
|
Woopen H, Richter R, Ismaeel F, Chekerov R, Roots I, Siepmann T, Sehouli J. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol 2016; 140:554-8. [PMID: 26790772 DOI: 10.1016/j.ygyno.2016.01.012] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 01/07/2016] [Accepted: 01/09/2016] [Indexed: 11/26/2022]
Abstract
BACKGROUND Ovarian cancer is mostly diagnosed in the elderly woman who is likely to have comorbid disease and to take several comedications on a regular basis. Aim of this study was to evaluate the influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival. PATIENTS AND METHODS In this individual participant data meta-analysis the original data of three phase II/III studies of the North-Eastern German Society of Gynecological Oncology (NOGGO) were analyzed using multivariate logistic and Cox regression. RESULTS Overall, 1213 patients with recurrent ovarian cancer were included in these analyses. An increasing amount of medication was associated with overall grade III/IV toxicity (p<0.001; OR 1.120), and hematological (p<0.001; OR 1.056) and non-hematological (p<0.001; OR 1.134) toxicities. Prior discontinuation of chemotherapy was not influenced by an increasing amount of medication (p=0.196). There was no association of polypharmacy with overall survival (p=0.068). CONCLUSION As polypharmacy does not influence survival ovarian cancer patients taking several comedications may be included in clinical trials and should not be deprived of adequate cancer treatment. However, a thorough monitoring is mandatory due to the increased risk of toxicities.
Collapse
Affiliation(s)
- H Woopen
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany; Dresden International University, Division of Health Care Sciences, Center for Clinical Research and Management Education, Freiberger Str. 37, 01067 Dresden, Germany.
| | - R Richter
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - F Ismaeel
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - R Chekerov
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
| | - I Roots
- Institute of Clinical Pharmacology and Toxicology, Charité - University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany
| | - T Siepmann
- Dresden International University, Division of Health Care Sciences, Center for Clinical Research and Management Education, Freiberger Str. 37, 01067 Dresden, Germany
| | - J Sehouli
- European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Charité - University Medicine of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
| |
Collapse
|
12
|
Schönborn I, Woopen H, Sernetz L. Vaginalkarzinom in der Schwangerschaft. Z Geburtshilfe Neonatol 2013. [DOI: 10.1055/s-0033-1361358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Woopen H, Sehouli J, Pietzner K, Darb-Esfahani S, Braicu E, Fotopoulou C. Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT). Eur J Obstet Gynecol Reprod Biol 2012; 165:313-7. [DOI: 10.1016/j.ejogrb.2012.07.034] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Revised: 06/28/2012] [Accepted: 07/29/2012] [Indexed: 11/24/2022]
|
14
|
Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012; 29:3416-20. [DOI: 10.1007/s12032-012-0285-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2012] [Accepted: 06/14/2012] [Indexed: 11/29/2022]
|
15
|
Sehouli J, Woopen H, Oskay-Öezcelik G. Aktuelle Therapiestrategien des malignen Ascites bei gynäkologischen Malignomen. Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1269981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|